SHIRE PHARMACEUTICALS LLC for SHIRE PHARMACEUTICALS LLC
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 1st Quarter - Report (this page) | Apr 20, 2012 | $100,000 | Replaced |
| 1st Quarter - Amendment | Jul 20, 2012 | $110,000 | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
Issues relating to R&D funding for rare disease products, biosimilars and other products; drug shortages; Prescription Drug User Fee Act (PDUFA) reauthorization; exclusivity periods; orphan drugs; fast track and accelerated approvals; health care reform implementation; drug innovation and patient access H.R. 2245, Preserving Access to Life Saving Medications Act; H.R. 3839, Drug Shortage Prevention Act of 2012; H.R. 3737, Unlocking Lifesaving Treatments for Rare-Diseases Act (ULTRA); H.R. 4132, Faster Access to Specialized Treatments (FAST) Act; S. 296, Preserving Access to Life Saving Medications Act; S. 606, Creating Hope Act; S. 2113, Transforming the Regulatory Environment to Accelerate Access to Treatment (TREAT) Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| EDWARD BUCKLEY | — |
Support LegiList
This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.